Clinical Trials Logo

Clinical Trial Summary

This trial studies how well a video-based intervention works in helping participants encourage their families to get tested for BRCA gene mutations. Testing in families with BRCA gene mutations can allow for risk management and reduction with the overall goal of reducing cancer burden. Video-based intervention sent via text messages may help participants easily share information about BRCA gene mutations with family members.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To understand whether the use of a video-based message to encourage cascade testing, delivered via short message service (SMS) (text message) or shared on social media, is superior to a written message as a method of information-sharing among families that have BRCA gene mutations. OUTLINE: Participants are randomized to 1 of 2 arms. ARM A: Participants receive a 2-minute information-graphic video via text message consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives that they can share with family via text message, email, or social media. ARM B: Participants receive family letter via U.S. postal service mail consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05264532
Study type Interventional
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State University Comprehsensive Cancer Center
Phone 1-800-293-5066
Email OSUCCCClinicaltrial@osumc.edu
Status Recruiting
Phase N/A
Start date April 5, 2018
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01907438 - Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Withdrawn NCT02309632 - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas N/A
Active, not recruiting NCT01009788 - ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Phase 2
Completed NCT01251874 - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Phase 1
Completed NCT02197000 - A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers N/A
Recruiting NCT03428802 - Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Phase 2
Completed NCT03377556 - Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Phase 2
Recruiting NCT04294927 - TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention N/A
Active, not recruiting NCT03943173 - Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Early Phase 1
Active, not recruiting NCT02953457 - Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Phase 2
Completed NCT01975363 - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer N/A
Completed NCT01948609 - Prospective Research of Outcomes After Salpingo-oophorectomy
Active, not recruiting NCT03552471 - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Phase 1
Recruiting NCT02225015 - Cancer Prevention in Women With a BRCA Mutation Phase 1
Active, not recruiting NCT02321228 - Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers N/A
Recruiting NCT04030559 - Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Phase 2
Terminated NCT01905592 - A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Phase 3
Recruiting NCT02474264 - The Link Between BRCA Mutation and Endothelial Function N/A
Active, not recruiting NCT02286687 - Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Phase 2